Iroko Says Eureka As It Presents Data Using Its Nano-Formulations In NSAIDs

Originally published in The Nano Newswire

Appearing before the American College of Rheumatology (ACR), Philadelphia-based Iroko Pharmaceuticals delivered clinical trial results of its Phase 2 research into the use of nano-formulations to deliver a large class of pain medicines known as NSAIDs (non-steroidal anti-inflammatory drugs).  In three presentations before the ACR in Chicago, the drug manufacturer presented evidence on how its applied proprietary nanotechnology reformulates certain products within available NSAIDs.

The research is an exciting development as the U.S. Food and Drug Administration (FDA) advises that NSAIDs should be administered at their lowest effective dose. With this in mind, "Iroko's nano-formulation program aims to lower the dosing and the systemic exposure to NSAIDs and thus improve their tolerability while maintaining their effectiveness." Commenting on the research, Dr. Allan Gibofsky, Professor of Medicine and Public Health at Weill Medical College of Cornell University, "[n]ano-formulated NSAIDs may provide a new treatment option if the potential indicated in these Phase 2 studies is confirmed in Phase 3 trials." John Vavricka, Iroko's C.E.O. of Iroko, stated, "[t]he ACR presentations are the most comprehensive report to date of our work in applying nanotechnology to medicines that are mainstays of pain management. It is these [sic] data that have given us the confidence to progress our clinical program into Phase 3 in anticipation of a 2012 regulatory filing to obtaining marketing approval of our first new product."  As NSAIDs are a mainstay in the treatment of pain, these research findings are encouraging to those in the medical and nanotechnology development fields.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.